A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Trial Profile

A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Porgaviximab (Primary)
  • Indications Ebola virus infections
  • Focus Therapeutic Use
  • Acronyms PREVAIL II
  • Most Recent Events

    • 13 Oct 2016 Results published in the New England Journal of Medicine
    • 12 Oct 2016 Primary endpoint has not been met. (Mortality), according to a Mapp Biopharmaceutical media release.
    • 12 Oct 2016 Results (n=72) published in a Mapp Biopharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top